פתחים סמויים מהעין

BCRX started with an Outperform at Leerink Swann; target $15 (7.56 )
	Leerink Swann initiates coverage of BioCryst Pharma with an Outperform rating and $15 target; firm believes the stock represents one of the most promising small-cap, targeted therapeutic cancer plays in the biotech sector, and that valuation will increase with greater visibility as to the medical and commercial potential of PNP inhibitors with which to treat T cell-mediated diseases.